PillScopolamine Transdermal System
Scopolamine
1 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
Who makes it1 active · 1 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Bryant Ranch Prepack | repackager | 1 | SUPPLYING |
| Padagis Israel Pharmaceuticals Ltd | unknown | 3 | EXITED 2028 |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Nov 3, 2025RESOLVEDShortage resolved: Scopolamine Transdermal System (Padagis US LLC)
Scopolamine Transdermal System — reported in shortage by Padagis US LLC. Therapeutic category: Gastroenterology, Neurology, Other.
- Nov 3, 2025SHORTAGEDrug shortage: Scopolamine Transdermal System (Padagis US LLC)
Scopolamine Transdermal System — reported in shortage by Padagis US LLC. Therapeutic category: Gastroenterology, Neurology, Other.
- May 11, 2018RECALLRecall (Class II): Scopolamine Transdermal Therapeutic System, 1 mg/3 days, a) 4-count (NDC 45802-580-84); b) 10-count (NDC 45802-580-46);…
Defective delivery system — Recalling firm: L. Perrigo Company — Nationwide in the U.S.A.